You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 21, 2025

Drugs in MeSH Category Dopamine Uptake Inhibitors


✉ Email this page to a colleague

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ferndale Labs FERNDEX dextroamphetamine sulfate TABLET;ORAL 084001-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Mylan Tech Viatris METHYLPHENIDATE methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 206497-003 Mar 14, 2022 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Takeda Pharms Usa VYVANSE lisdexamfetamine dimesylate CAPSULE;ORAL 021977-003 Feb 23, 2007 AB RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Prinston Inc LISDEXAMFETAMINE DIMESYLATE lisdexamfetamine dimesylate CAPSULE;ORAL 216266-004 Aug 25, 2023 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Oxford Pharms BENZTROPINE MESYLATE benztropine mesylate TABLET;ORAL 040706-001 Feb 14, 2008 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Tris Pharma Inc DEXMETHYLPHENIDATE HYDROCHLORIDE dexmethylphenidate hydrochloride TABLET;ORAL 207901-002 Aug 26, 2016 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Ascent Pharms Inc DEXMETHYLPHENIDATE HYDROCHLORIDE dexmethylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 215523-002 Dec 8, 2021 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Dopamine Uptake Inhibitors Market Analysis and Financial Projection

The market for dopamine uptake inhibitors (DUIs) is shaped by evolving therapeutic applications, patent strategies, and competitive dynamics across neurological and psychiatric disorders. Here's a detailed analysis:


Market Dynamics

Growth Drivers

  • Expanding Mental Health Needs: The global antidepressant market, valued at $20.11B in 2025, is projected to grow at a 7.4% CAGR through 2032[4]. While SSRIs dominate this space (48.1% market share)[4], DUIs like bupropion (an NDRI) are gaining traction for treatment-resistant depression (TRD) and smoking cessation[17].
  • Emergence of Atypical DUIs: Compounds such as modafinil and JHW007 show promise due to lower abuse potential compared to traditional psychostimulants. These are being explored for ADHD, cocaine addiction, and Parkinson’s disease[13][16].
  • Technological Advancements: AI-driven drug discovery (e.g., Exscientia’s DSP-1181) accelerates DUI development, though structural similarities to older drugs like haloperidol raise questions about novelty[2][3].

Key Therapeutic Segments

  1. Depression: SNRIs and SSRIs lead the market, but DUIs like bupropion address TRD. Aplenzin (bupropion HBr) could capture a $3B+ opportunity if approved for TRD by 2026[17].
  2. ADHD: Methylphenidate, a DUI, remains a cornerstone treatment with a multimodal mechanism[11].
  3. Neurodegenerative Diseases: DUIs like mito-apocynin are studied for Parkinson’s disease due to neuroprotective effects against oxidative stress[10].

Challenges

  • Safety Concerns: Side effects (e.g., dry mouth, agitation) limit long-term adherence[11].
  • Complex CNS Drug Development: High attrition rates persist due to blood-brain barrier challenges and target specificity[3].

Patent Landscape

Key Patents and Players

Drug/Patent Assignee Expiry Innovation
Bupropion (Aplenzin) Bausch Health ~2026+ Extended use patents for TRD; potential for 20-year evergreen status[17].
CDTP-32476 Undisclosed Pending Slow-onset DUI with reduced abuse potential; enantiomer separation achieved[16].
Benztropinamine Analogs Undisclosed Pending Novel DUIs targeting dopamine transporters for addiction treatment[14].
DSP-1181 Exscientia/Sumitomo Post-2030 AI-designed 5-HT1a agonist (structurally similar to haloperidol)[2].

Strategies

  • Patent Extensions: Companies like Bausch leverage new indications (e.g., TRD) to prolong exclusivity[17].
  • Structural Modifications: Slow-onset DUIs (e.g., CDTP-32476) aim to reduce abuse liability while maintaining efficacy[16].
  • AI/ML Integration: Firms use machine learning to optimize BBB permeability and target engagement for CNS drugs[3][10].

Regional and Competitive Insights

  • North America: Holds 42.3% market share in antidepressants (2023), driven by high mental disorder prevalence[1].
  • Asia-Pacific: Emerging growth due to rising awareness and AI adoption in drug discovery[3][15].
  • Key Players: Novo Nordisk (semaglutide patents)[5], Bausch Health (bupropion), and Exscientia (AI-driven candidates)[2][17].

Opportunities and Trends

  1. Combination Therapies: DUIs paired with antioxidants (e.g., mito-apocynin) for neurodegenerative diseases[10].
  2. Abuse-Resistant Formulations: Atypical DUIs like JHW007 may disrupt stimulant addiction markets[13].
  3. Digital Health Integration: EEG-based screening tools accelerate DUI development by predicting neuroactivity[13].

Key Takeaways

  • Market Growth: Antidepressant and DUI markets are projected to exceed $30B by 2033, with SNRIs/SSRIs leading but DUIs gaining ground[1][7][15].
  • Innovation Focus: AI and structural modifications drive patent filings, while safety and efficacy remain critical.
  • Unmet Needs: TRD and neuroprotection in Parkinson’s present significant commercial opportunities[10][17].

By addressing niche indications and leveraging novel technologies, DUIs are poised to expand their role in neurology and psychiatry despite developmental hurdles.

References

  1. https://market.us/report/antidepressants-drugs-market/
  2. https://www.cas.org/resources/cas-insights/ai-drug-discovery-assessing-the-first-ai-designed-drug-candidates-to-go-into-human-clinical-trials
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC8043990/
  4. https://www.coherentmarketinsights.com/industry-reports/antidepressant-market
  5. https://www.keionline.org/wp-content/uploads/KEI-BN-2024-1.pdf
  6. https://en.wikipedia.org/wiki/Antipsychotic
  7. https://www.imarcgroup.com/depression-drugs-market
  8. https://patents.google.com/patent/WO2005067931A2/en
  9. https://meshb.nlm.nih.gov/record/ui?ui=D018765
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC4995106/
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC8455398/
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC3758386/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC8369976/
  14. https://patents.google.com/patent/WO2006135715A1/ja
  15. https://www.einpresswire.com/article/590864051/dopamine-and-norepinephrine-reuptake-inhibitor-market-to-perceive-biggest-trend-and-trending-opportunity-by-2032-qmi
  16. https://pubs.acs.org/doi/10.1021/acsomega.3c02997
  17. https://www.investing.com/analysis/bausch-potential-breakthrough-in-depression-treatment-to-unlock-3b-opportunity-200658563
  18. https://www.maxval.com/blog/pharma-patent-landscape-parkinsons-disease-uncovered/
  19. https://www.psychiatrictimes.com/view/new-hope-depression-horizon
Last updated: 2025-03-24

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.